MedTrace Logo

The Registry Study of Genetic Alterations of Melanoma in Taiwan

NCT06952400 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2025-05-06

No results posted yet for this study

Summary

Cutaneous melanoma is the most aggressive malignancy in skin cancers. Cutaneous melanoma is a rare disease in Taiwan with an incidence rate of around 1/100,000. Acral lentiginous melanoma is the most common subtype and comprises more than half of cutaneous melanoma in Asia including Taiwan but only 1% in Caucasians. In addition, mucosal melanoma accounts for more than 20% of malignancy melanoma in Taiwan but only 1% in Caucasians. Acral and mucosal melanomas have distinct epidemiological, clinical, pathological and genetic features from non-acral melanoma which is commonly seen in Western countries. Comparing with melanoma in Caucasians, Asian melanoma has higher recurrence rate after primary surgery, lower response rate to immunotherapy, and shorter progression-free survival for immunotherapy and targeted therapy leading generally poor survival outcomes regardless stage.

Conditions

  • Primary Melanoma of the Extremity

Sponsors & Collaborators

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Chiao-En Wu, MD, PhD · Chang Gung Medical Foundation

  • Tsang-Wu Liu, MD · Taiwan Cooperative Oncology Group,National Health Research Institutes, Taiwan

  • Nai-Jung Chiang, MD, PhD · Taiwan Cooperative Oncology Group,National Health Research Institutes, Taiwan

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-08-22
Primary Completion
2025-12-31
Completion
2030-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06952400 on ClinicalTrials.gov